How about this:
I wonder why they are trying to pursue a dozen indications half-a$$. Why not focus 90% on a big, fat, undeniable launch of Brilacidin and secure and finance our future? And more importantly, create some credibility with the more mainstream and likely less-informed investor, who seems to be losing a bit of confidence.
Instead of announcing all these new (and probably potentially great) drugs. All this does momentarily, is create a "Oh look, there's another one, let's see how long it takes before it fizzles"-vibe.
I'm not one of them, don't get me wrong, I love the widespread potential of the platform, but that's what I'm detecting in the general sentiment of several message boards lately.
Of course, I too believe that we're all singing a far more positive tune here rather soon!!
GLTA!
News 
Market Data 
Discover 
